No Data
No Data
Swhy: The penetration rate continues to increase coupled with the rise of domestic products, bullish on the cosmetic and medical beauty sector.
The medical beauty industry will continue to benefit from a rich supply of products and maintain healthy development through industry standardization.
CITIC Securities: the collagen industry's prosperity continues with significant growth among various leading companies, and there is ample potential for the future.
According to the Zhitong Finance APP, Citic Securities research report believes that the sales of restructured collagen products have been excellent, with brands such as Weweima, Kelifu, and Viyimi performing well this year.
Returns On Capital Signal Tricky Times Ahead For Guangdong Marubi Biotechnology (SHSE:603983)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earn
Subdued Growth No Barrier To Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Price
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 31x, you may consider Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) as a stock to potentially avoid
Marumi Co., Ltd. (603983.SH) 2023 equity distribution: $0.52 per share, share registration on May 30
Marumi Co., Ltd. (603983.SH) issued the 2023 equity distribution implementation notice. This time, profits are distributed to Israel...
Marumi Co., Ltd. (603983.SH): Not involved in hyaluronic acid-related medical and aesthetic projects
Gelonghui, May 23丨Marumi Co., Ltd. (603983.SH) said on an interactive platform that the company has not yet been involved in hyaluronic acid-related medical and aesthetic projects.
No Data